Medical Care Technologies Inc. (OTCID:MDCE) Outlines Operating Focus With Growing Software and Subsidiary Revenue Activity Ahead of Q3 Results 
How Braden Business Systems Use Auvik SaaS Management
to Identify, Secure, and Manage SaaS Sprawl About Braden Business Systems & Jon Fitzryk Since 1989, Braden Business Systems has...
Efficient Network Management: A Dive into Auvik Network Management’s Robust Features
In today's fast-paced digital world, efficient and effective network management has become more important than ever. With businesses relying heavily...
Medical Care Technologies Inc. (OTCID:MDCE) Outlines Operating Focus With Growing Software and Subsidiary Revenue Activity Ahead of Q3 Results
AI Software Focus Delivers Paid Work While Infinite Auctions and Real Game Used Build Revenue Ahead of Q3 Results MESA,...
Modular Medical Completes Comprehensive Patient Market Research Study with Thrivable, Reinforcing Strong Interest in Simplified Insulin Delivery
More Than 540 People with Diabetes Participated in a Three-Phase Study of Treatment Burden, Pump Adoption Barriers and Perceptions of...
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering...
Releaf Unveils UK-first THCV for Weight Management
Releaf becomes first UK medical cannabis clinic to offer THCV since 1973, for weight managementReleaf becomes the first medical cannabis...
Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
Capital efficiency strategy prioritizes CD228V development while seeking separate public listing for SkinJect® and partners to advance Teverelix® PHILADELPHIA, PA...
KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results
New York, New York--(Newsfile Corp. - November 9, 2026) - KALA BIO, Inc. (NASDAQ: KALA) today announced preliminary unaudited financial...
Adia Med CEO Larry Powalisz Issues Open Letter on Leadership Journey, Research Mission, and Progress Since 2024
Winter Park, Florida--(Newsfile Corp. - November 9, 2026) - Adia Med Inc. (OTCQB: ADIA) today released the following open letter...
Rhelion Life Sciences’ Wholly Owned Subsidiary Filament Health Ships PEX010 to King’s College London
Filament has shipped PEX010 to King's College London for SLEEPY, a feasibility study of giving psilocybin just before sleep.Toronto, Ontario--(Newsfile...
Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma; Potential to Decrease Morbidities and Surgical FatigueKing of...
BMZ Battery Solutions Group to Introduce High-Energy-Density E-Bike Battery to U.S. Market at Micromobility America
POWER2RIDE RB-900 combines 940 Wh capacity, lightweight design and flexible integration to help electric bicycle manufacturers meet growing performance and...
AI Predicts PTSD Risk Based on Stories About What Brought Patients to the Emergency Room
NEW YORK, Nov. 9, 2026 /PRNewswire/ -- An AI tool can analyze patients' narratives about injuries that sent them to...
iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
— Collaboration’s objective is to evaluate the potential of a cancer therapeutic by using iDEL’s unique shuttle technology platform —...
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on...
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on...
GENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027
Comprehensive clinical and scientific data supporting Phase 2 development of nangibotide in ACLF unveiled to leading experts during AASLD The...
Essential Pharma and Nordmark announce new partnership and UK availability of Norzyme® (pancreas powder) 25,000 gastro-resistant capsules for pancreatic exocrine insufficiency
Partnership brings together decades of pancreatin experience at Nordmark and Essential PharmaNorzyme® (pancreas powder) 25,000 gastro-resistant capsules, a Nordmark medicine,...
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
Data from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging...
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total...
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A...
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
Pairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biologyExtends argenx’s immunology innovation...